Taro Pharmaceutical Industries Ltd. TARO (“Taro”) and Sun
Pharmaceutical Industries Ltd. (together with its subsidiaries, “Sun Pharma”)
announced today that they have mutually agreed to terminate their merger
agreement, announced in August 2012, pursuant to which all shareholders of
Taro (other than Sun Pharma and its affiliates) would have received a cash
payment of $39.50 per share upon the closing of the merger.
Each of Sun Pharma and Taro (at the direction of the Special Committee) agreed
that terminating the merger agreement was in the best interest of the
respective companies and shareholders.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in